Potassium acetate

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	C2H3O2.K
Molecular Weight	98.1423
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[K+].CC([O-])=O

InChI

InChIKey=SCVFZCLFOSHCOH-UHFFFAOYSA-M

InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C2H3O2
Molecular Weight	59.044
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29764543 | https://www.mayoclinic.org/drugs-supplements/potassium-supplement-oral-route-parenteral-route/description/drg-20070753 | https://www.ncbi.nlm.nih.gov/pubmed/28419159

Potassium is needed to maintain good health. When potassium level falls below 3.5 mmol/L, Hypokalemia is diagnosed. In case of extremely low level of potassium (lower than 2.5 mmol/L) the following symptoms are appeared: malaise and fatigue. This low level of potassium can lead to severe muscle weakness and paralysis; respiratory failure; intermittent muscle spasms. It is known, foods that are good sources of potassium and low in sodium may reduce the risk of high blood pressure and stroke. Potassium supplementation is also recommended as an adjuvant antihypertensive agent for patients with essential hypertension.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
essential hypertension 16 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28419159	Palliative		Phase III 665	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Crystal structures of Tritrichomonasfoetus inosine monophosphate dehydrogenase in complex with substrate, cofactor and analogs: a structural basis for the random-in ordered-out kinetic mechanism.	2003-02-14	12559919
Delay of natural bone loss by higher intakes of specific minerals and vitamins.	2001-05	11401244
Inhibition of HIV-1 infection by zinc group metal compounds.	1999-09	10517314
Diet, genetics and hypertension.	1997-08	9263178
Mineral and water nutrition.	1991-07	1893277
Age sensitivity to organophosphate-induced delayed polyneuropathy. Biochemical and toxicological studies in developing chicks.	1991-05-15	2018554

Patents

Sample Use Guides

In Vivo Use Guide

Potassium is administered in various dosage forms (gluconate, citrate, chloride, bicarbonate). Exact dose should be determined by a doctor. Most people will not take more than 100 mEq a day.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:47:30 GMT 2025` Edited by `admin` on `Mon Mar 31 17:47:30 GMT 2025`
Record UNII	M911911U02
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

KALI ACETICUM

Preferred Name

English

Potassium acetate

Official Name

English

POTASSIUM ACETATE [VANDF]

Common Name

English

FEMA NO. 2920

Code

English

E-261

Code

English

POTASSIUM ACETATE [JAN]

Common Name

English

POTASSIUM ACETATE [FHFI]

Common Name

English

POTASSIUM ACETATE [MART.]

Common Name

English

POTASSIUM ACETATE [MI]

Common Name

English

KALI ACETICUM [HPUS]

Common Name

English

ACETIC ACID, POTASSIUM SALT (1:1)

Common Name

English

INS NO.261

Code

English

ACETIC ACID, POTASSIUM SALT

Common Name

English

INS-261(I)

Code

English

POTASSIUM ACETATES

Common Name

English

POTASSIUM ACETATE [USP MONOGRAPH]

Common Name

English

Potassium acetate [WHO-DD]

Common Name

English

POTASSIUM ACETATE [EP MONOGRAPH]

Common Name

English

POTASSIUM ACETATE [II]

Common Name

English

POTASSIUM ACETATE [USP-RS]

Common Name

English

INS-261

Code

English

POTASSIUM ACETATE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QB05XA17